Cargando…

PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium

We performed this study to investigate the diagnostic performance of prostate-specific antigen density (PSAD) in a multicenter cohort of the Chinese Prostate Cancer Consortium. Outpatients with prostate-specific antigen (PSA) levels ≥4.0 ng ml(−1) regardless of digital rectal examination (DRE) resul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Zi-Jian, Qian, Jin-Ke, Yang, Yue, Wu, Han-Xiao, Wang, Mao-Yu, Jiang, Si-Yuan, Wang, Fu-Bo, Zhang, Wei, Chen, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152427/ https://www.ncbi.nlm.nih.gov/pubmed/33208562 http://dx.doi.org/10.4103/aja.aja_61_20

Ejemplares similares

Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0–10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium
por: Chen, Rui, et al.
Publicado: (2015)

Evaluation of PSA-age volume score in predicting prostate cancer in Chinese population
por: Wu, Yi-Shuo, et al.
Publicado: (2018)

The role of PSA density in the MRI pathway for prostate cancer diagnostics
por: Cash, Hannes, et al.
Publicado: (2022)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml(–1)
por: Wang, Cheng, et al.
Publicado: (2021)

Correction to: The role of PSA density in the MRI pathway for prostate cancer diagnostics
por: Cash, Hannes, et al.
Publicado: (2023)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
por: Lee, Jaegeun, et al.
Publicado: (2021)

Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution
por: Nan, Li-Bin, et al.
Publicado: (2019)

Incidence of Histological Prostatitis and Its Correlation with PSA Density
por: Piovesan, Affonso Celso, et al.
Publicado: (2009)

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5–10.0 ng ml(-1) and 10.1–20.0 ng ml(-1): a multicenter study
por: Lin, Yu-Rong, et al.
Publicado: (2015)

Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer
por: Tang, Qionghua, et al.
Publicado: (2022)

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
por: Kotb, A F, et al.
Publicado: (2011)

Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes
por: Llop, Esther, et al.
Publicado: (2016)

Clinical evaluation of prostate cancer gene 3 score in diagnosis among Chinese men with prostate cancer and benign prostatic hyperplasia
por: Huang, Jin, et al.
Publicado: (2015)

Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score
por: Fang, Dong, et al.
Publicado: (2015)

Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI
por: Ma, Zengni, et al.
Publicado: (2023)

Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models
por: Chen, Ming, et al.
Publicado: (2021)

Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2023)

AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score
por: Fang, Dong, et al.
Publicado: (2016)

Usefulness of Total PSA Value in Prostate Diseases Diagnosis
por: Prcic, Alden, et al.
Publicado: (2016)

Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes: Erratum
por: Llop, Esther, et al.
Publicado: (2018)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

Optimized Identification of High-Grade Prostate Cancer by Combining Different PSA Molecular Forms and PSA Density in a Deep Learning Model
por: Gentile, Francesco, et al.
Publicado: (2021)

Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial
por: Pye, Hayley, et al.
Publicado: (2021)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Metastatic prostate cancer in the modern era of PSA screening
por: Fontenot, Philip A., et al.
Publicado: (2017)

Characterisation of the main PSA glycoforms in aggressive prostate cancer
por: Gratacós-Mulleras, Anna, et al.
Publicado: (2020)

Genetically adjusted PSA levels for prostate cancer screening
por: Kachuri, Linda, et al.
Publicado: (2023)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer
por: Zou, Bing-Zi, et al.
Publicado: (2023)

General practitioners’ reflections on using PSA for diagnosis of prostate cancer. A qualitative study
por: Thorsen, Olav, et al.
Publicado: (2022)

PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: implications in precision diagnosis
por: Akizhanova, Mariyam, et al.
Publicado: (2017)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Detection of Prostate Cancer Antigen 3 and Prostate Cancer Susceptibility Candidate in Non-DRE Urine Improves Diagnosis of Prostate Cancer in Chinese Population
por: Ye, Lie-Fu, et al.
Publicado: (2020)

Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men
por: Coric, Jozo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qprslf69jqds3moh5kslt7mp8a